Browse by author
Lookup NU author(s): Dr Daniel ErskineORCiD
This is the authors' accepted manuscript of a review published in its final definitive form in 2019. For re-use rights please refer to the publishers terms and conditions.
Synucleinopathies including Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) are characterized by the abnormal accumulation and propagation of α‐synuclein (α‐syn) pathology in the central and peripheral nervous system as Lewy bodies or glial cytoplasmic inclusions. Several antibodies against α‐syn have been developed since it was first detected as the major component of Lewy bodies and glial cytoplasmic inclusions. Over the years, researchers have generated specific antibodies that alleviate the accumulation of intracellular aggregated α‐syn and associated pathology in cellular and preclinical models of synucleinopathies. So far, antibodies have been the first choice as tools for research and diagnosis and currently, a wide variety of antibody fragments have been developed as an alternative to full‐length antibodies for increasing its therapeutic usefulness. Recently, conformation specific antibody‐based approaches have been found to be promising as therapeutic strategies, both to block α‐syn aggregation and ameliorate the resultant cytotoxicity, and as diagnostic tools. In this review we summarize different α‐syn specific antibodies and provide their usefulness in tackling synucleinopathies.
Author(s): Vaikath NN, Hmila I, Gupta V, Erskine D, Ingelsson M, El-Agnaf OMA
Publication type: Review
Publication status: Published
Journal: Journal of Neurochemistry
Year: 2019
Volume: 150
Issue: 5
Pages: 612-625
Print publication date: 01/09/2019
Online publication date: 04/05/2019
Acceptance date: 01/05/2019
ISSN (print): 0022-3042
ISSN (electronic): 1471-4159
URL: https://doi.org/10.1111/jnc.14713
DOI: 10.1111/jnc.14713
PubMed id: 31055836
